News

Cubist Pharma made this decision after reviewing top line efficacy and safety data from the CB-500,929 Phase 2 Conserv 1 and Conserv 2 trials. Cubist Pharma said that

The complete response letter identifies issues that would have to be addressed before re-submission, including the generation of additional clinical data. ProStrakan plans to meet with the FDA

The Phase III safety study is randomised, double-blinded trial comparing the safety profile of CIP- Isotretinoin to an FDA-approved, commercially available isotretinoin product. The study is currently being

Reportedly, Vivus failed to start the Luramist Phase 3 trial by the outside date of 1 April 2010 that was set by the independent arbitration panel, convened by

In addition, as per the agreement, Biohit will cross-promote BioCision’s thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes. Michelle Nemits, vice president of sales and

Revenue management solutions are part of McKesson’s comprehensive portfolio of physician solutions designed to reduce time spent on administrative tasks and streamline practice operations. As the source for

The lawsuits relate to the quality and formulation of Oxaliplatin, available in the US under the brand name Eloxatin. The settlement agreements are subject to review by the

Futura Medical is expecting that the regulatory dossier for CSD500, will allow the CE mark approval process to be completed later in 2010. Futura Medical said the submission

Abbott’s test would be able to detect NGAL about two days earlier than the widely used method for the detection of AKI, a serum creatinine blood test. According